Fibroblast Growth Factor-23 and Risk of Cardiovascular Diseases A Mendelian Randomization Study

被引:10
作者
Donovan, Killian [1 ,2 ]
Herrington, William G. [1 ,2 ,3 ,4 ]
Pare, Guillaume [5 ]
Pigeyre, Marie [5 ]
Haynes, Richard [1 ,2 ,3 ,4 ]
Sardell, Rebecca [1 ,2 ]
Butterworth, Adam S. [6 ]
Folkersen, Lasse [7 ]
Gustafsson, Stefan [8 ]
Wang, Qin [9 ]
Baigent, Colin [1 ,2 ,3 ]
Malarstig, Anders [10 ]
Holmes, Michael V. [1 ,2 ,3 ,11 ]
Staplin, Natalie [1 ,2 ,3 ,11 ]
机构
[1] Univ Oxford, Nuffield Dept Populat Hlth NDPH, Clin Trial Serv Unit, Oxford, England
[2] Univ Oxford, Nuffield Dept Populat Hlth NDPH, Epidemiol Studies Unit, Oxford, England
[3] Univ Oxford, NDPH, Med Res Council Populat Hlth Res Unit, Oxford, England
[4] Churchill Hosp, Oxford Kidney Unit, Oxford, England
[5] McMaster Univ, Populat Hlth Res Inst, Hamilton, ON, Canada
[6] Univ Cambridge, Dept Publ Hlth & Primary Care, BHF Cardiovasc Epidemiol Unit, Cambridge, England
[7] Danish Natl Genome Ctr, Copenhagen, Denmark
[8] Uppsala Univ, Dept Med Sci, Mol Epidemiol & Sci Life Lab, Uppsala, Sweden
[9] Baker Heart & Diabet Inst, Syst Epidemiol, Melbourne, Vic, Australia
[10] Karolinska Inst, Dept Med Epidemiol & Biostat, Solna, Sweden
[11] Univ Oxford, Big Data Inst, Li Ka Shing Ctr Hlth Informat & Discovery, Oxford, England
来源
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY | 2023年 / 18卷 / 01期
基金
英国医学研究理事会;
关键词
CHRONIC KIDNEY-DISEASE; PARATHYROID-HORMONE; GENERAL-POPULATION; ALL-CAUSE; ASSOCIATION; MORTALITY; OUTCOMES;
D O I
10.2215/CJN.05080422
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background Fibroblast growth factor-23 (FGF-23) is associated with a range of cardiovascular and noncardiovascular diseases in conventional epidemiological studies, but substantial residual confounding may exist. Mendelian randomization approaches can help control for such confounding.Methods SCALLOP Consortium data of 19,195 participants were used to generate an FGF-23 genetic score. Data from 337,448 UK Biobank participants were used to estimate associations between higher genetically predicted FGF-23 concentration and the odds of any atherosclerotic cardiovascular disease (n=26,266 events), nonatherosclerotic cardiovascular disease (n=12,652), and noncardiovascular diseases previously linked to FGF-23. Measurements of carotid intima-media thickness and left ventricular mass were available in a subset. Associations with cardiovascular outcomes were also tested in three large case-control consortia: CARDIOGRAMplusC4D (coronary artery disease, n=181,249 cases), MEGASTROKE (stroke, n=34,217), and HERMES (heart failure, n=47,309).Results We identified 34 independent variants for circulating FGF-23, which formed a validated genetic score. There were no associations between genetically predicted FGF-23 and any of the cardiovascular or non cardiovascular outcomes. In UK Biobank, the odds ratio (OR) for any atherosclerotic cardiovascular disease per 1-SD higher genetically predicted logFGF-23 was 1.03 (95% confidence interval [95% CI], 0.98 to 1.08), and for any nonatherosclerotic cardiovascular disease, it was 1.01 (95% CI, 0.94 to 1.09). The ORs in the case-control consortia were 1.00 (95% CI, 0.97 to 1.03) for coronary artery disease, 1.01 (95% CI, 0.95 to 1.07) for stroke, and 1.00 (95% CI, 0.95 to 1.05) for heart failure. In those with imaging, logFGF-23 was not associated with carotid or cardiac abnormalities.Conclusions Genetically predicted FGF-23 levels are not associated with atherosclerotic and nonatherosclerotic cardiovascular diseases, suggesting no important causal link.
引用
收藏
页码:17 / 27
页数:11
相关论文
共 47 条
  • [1] Association of Genetically Predicted Fibroblast Growth Factor-23 with Heart Failure A Mendelian Randomization Study
    Akwo, Elvis
    Pike, Mindy M.
    Ertuglu, Lale A.
    Vartanian, Nicholas
    Farber-Eger, Eric
    Lipworth, Loren
    Perwad, Farzana
    Siew, Edward
    Hung, Adriana
    Bansal, Nisha
    de Boer, Ian
    Kestenbaum, Bryan
    Cox, Nancy J.
    Ikizler, T. Alp
    Wells, Quinn
    Robinson-Cohen, Cassianne
    [J]. CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2022, 17 (08): : 1183 - 1193
  • [2] Aragam KG, 2021, MEDRXIV
  • [3] A population-based phenome-wide association study of cardiac and aortic structure and function
    Bai, Wenjia
    Suzuki, Hideaki
    Huang, Jian
    Francis, Catherine
    Wang, Shuo
    Tarroni, Giacomo
    Guitton, Florian
    Aung, Nay
    Fung, Kenneth
    Petersen, Steffen E.
    Piechnik, Stefan K.
    Neubauer, Stefan
    Evangelou, Evangelos
    Dehghan, Abbas
    O'Regan, Declan P.
    Wilkins, Martin R.
    Guo, Yike
    Matthews, Paul M.
    Rueckert, Daniel
    [J]. NATURE MEDICINE, 2020, 26 (10) : 1654 - +
  • [4] Mendelian randomisation in cardiovascular research: an introduction for clinicians
    Bennett, Derrick A.
    Holmes, Michael V.
    [J]. HEART, 2017, 103 (18) : 1400 - 1407
  • [5] Improving the accuracy of two-sample summary-data Mendelian randomization: moving beyond the NOME assumption
    Bowden, Jack
    Del Greco, Fabiola M.
    Minelli, Cosetta
    Zhao, Qingyuan
    Lawlor, Debbie A.
    Sheehan, Nuala A.
    Thompson, John
    Smith, George Davey
    [J]. INTERNATIONAL JOURNAL OF EPIDEMIOLOGY, 2019, 48 (03) : 728 - 742
  • [6] Fibroblast Growth Factor-23 and the Long-Term Risk of Hospital-Associated AKI among Community-Dwelling Older Individuals
    Brown, Jeremiah R.
    Katz, Ronit
    Ix, Joachim H.
    de Boer, Ian H.
    Siscovick, David S.
    Grams, Morgan E.
    Shlipak, Michael
    Sarnak, Mark J.
    [J]. CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2014, 9 (02): : 239 - 246
  • [7] Sensitivity Analyses for Robust Causal Inference from Mendelian Randomization Analyses with Multiple Genetic Variants
    Burgess, Stephen
    Bowden, Jack
    Fall, Tove
    Ingelsson, Erik
    Thompson, Simon G.
    [J]. EPIDEMIOLOGY, 2017, 28 (01) : 30 - 42
  • [8] The UK Biobank resource with deep phenotyping and genomic data
    Bycroft, Clare
    Freeman, Colin
    Petkova, Desislava
    Band, Gavin
    Elliott, Lloyd T.
    Sharp, Kevin
    Motyer, Allan
    Vukcevic, Damjan
    Delaneau, Olivier
    O'Connell, Jared
    Cortes, Adrian
    Welsh, Samantha
    Young, Alan
    Effingham, Mark
    McVean, Gil
    Leslie, Stephen
    Allen, Naomi
    Donnelly, Peter
    Marchini, Jonathan
    [J]. NATURE, 2018, 562 (7726) : 203 - +
  • [9] Bone and mineral disorders in chronic kidney disease: implications for cardiovascular health and ageing in the general population
    Covic, Adrian
    Vervloet, Marc
    Massy, Ziad A.
    Torres, Pablo Urena
    Goldsmith, David
    Brandenburg, Vincent
    Mazzaferro, Sandro
    Evenepoel, Pieter
    Bover, Jordi
    Apetrii, Mugurel
    Cozzolino, Mario
    [J]. LANCET DIABETES & ENDOCRINOLOGY, 2018, 6 (04) : 319 - 331
  • [10] Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians
    Davies, Neil M.
    Holmes, Michael V.
    Smith, George Davey
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2018, 362